Rare-Earth Metallocenes for Polymerization of Olefins and Conjugated Dienes: From Fundamental Studies to Olefin Block Copolymers.

The various steps in the mechanism of olefin polymerizations mediated by neutral rare-earth metallocene complexes are discussed. The complexes are either trivalent hydride and alkyl rare-earth compounds or divalent metallocenes that are activated by the monomer via an oxidation step. The stereospecific polymerizations of conjugated dienes based on the association of a cationic metallocene complex and an alkylaluminum and the polymerization mechanism based on monomer insertion into an aluminum-carbon bond are also discussed.

Nitriles as Functionalization and Coupling Agents for Polyolefins Obtained by Coordinative Chain Transfer Polymerization.

Coordinative chain transfer polymerization (CCTP) of ethylene and its copolymerization with 1,3-butadiene is conducted in toluene at 80 °C using a combination of {(MeSi(CH))Nd(μ-BH)[(μ-BH)Li(THF)]} (1) metal complex and various organomagnesium compounds used as chain transfer agents including n-butyl-n-octyl-magnesium (BOMAG), n-butyl-mesityl-magnesium (n-BuMgMes), n-butyl-magnesium chloride (n-BuMgCl), n-pentyl-magnesium bromide (n-CHMgBr), pentanediyl-1,5-di(magnesium bromide) (PDMB) and isobutyl-magnesium chloride (i-BuMgCl). Kinetics and performance in terms of control of the (co)polymerization are comparatively discussed particularly considering the presence of ether and the nature of the organomagnesium compounds employed. Taking advantage of the well-known reactivity between nitrile and molecular organomagnesium compounds, the functionalization of the chains is further carried out by deactivation of the polymerization medium with benzonitrile or methoxybenzonitrile compounds leading to ketone ω-functionalized chains.

[A case of pyroglutamic metabolic acidosis after cotreatment by flucloxacillin and paracetamol].

We report on the case of a 73-year-old man, who was referred to our emergency department for confusion and dyspnea. He had been under a treatment of flucloxacillin for six weeks because of a possible methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis that was complicated by an acute late infection of a knee prosthesis. The laboratory work-up revealed a metabolic acidosis with a high anion gap.

Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology.

Antibody-drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients.

Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer.

With three clinically approved antibody-drug conjugates targeting HER2, this target is clearly identified to be of interest in oncology. Moreover, the advent of new bioconjugation technologies producing site-specific homogenous conjugates led to the opportunity of developing new medicines linking antibodies and payloads. Here, a new relevant HER2-targeting ADC was obtained by the conjugation of monomethyl auristatin E onto trastuzumab using McSAF Inside bioconjugation technology.